 "Corbion and MedinCell form JV to supply bio-based polymers for controlled release drugs")
Corbion, the Dutch manufacturer of bio-based materials, has formed a 50:50 joint venture with MedinCell for the supply of PEG (polyethyleneglycol) and PLA (polylactic acid) based co-polymers in the field of controlled release drug delivery.
The joint venture, CM Biomaterials, will sell the PEG & PLA co-polymers to MedinCell partners who license the MedinCell controlled release technology, BEPO. Manufacturing of the polymers will take place in Corbion’s medical biomaterials plants in the US and the Netherlands, while development and licensing of the technology remain the exclusive responsibility of MedinCell. CM Biomaterials will be established in the Netherlands.
Marco Bootz, SVP Biochemicals, Corbion, said, “Corbion and MedinCell have been in a joint development program since 2010, to optimise the manufacturing of PEG/PLA polymers for drug delivery. This cooperation has now successfully developed into a joint venture for the supply of PEG/PLA polymers. In this joint venture, Corbion will be responsible for manufacturing the polymers and with our complementary expertise in the field of polymers we will together develop the optimal polymers for MedinCell’s applications. This new technology will further enhance our position in medical biomaterials.”
Christophe Douat, CEO of MedinCell, added, “The creation of CM Biomaterials validates our balanced network company model that aims to gather leaders in many fields to create best-in-class medicines for Global Health. Based on a complementary partnership, CM Biomaterials will best serve BEPO partners and secure the quality of the polymers used for all BEPO applications.”
Based on a combination of co-polymers, solvent and active pharmaceutical ingredient (API), the BEPO technology can provide a controlled release of drug for days, weeks or months from a fully biodegradable depot that forms after subcutaneous injection or local delivery of the formulated API. As a game-changing technology, BEPO combines many advantages compared to alternative drug delivery technologies, including improved patient compliance, efficacy and tolerability, as well as, versatility, development speed and lower manufacturing costs.
The joint venture, CM Biomaterials, will sell the PEG & PLA co-polymers to MedinCell partners who license the MedinCell controlled release technology, BEPO. Manufacturing of the polymers will take place in Corbion’s medical biomaterials plants in the US and the Netherlands, while development and licensing of the technology remain the exclusive responsibility of MedinCell. CM Biomaterials will be established in the Netherlands.
Marco Bootz, SVP Biochemicals, Corbion, said, “Corbion and MedinCell have been in a joint development program since 2010, to optimise the manufacturing of PEG/PLA polymers for drug delivery. This cooperation has now successfully developed into a joint venture for the supply of PEG/PLA polymers. In this joint venture, Corbion will be responsible for manufacturing the polymers and with our complementary expertise in the field of polymers we will together develop the optimal polymers for MedinCell’s applications. This new technology will further enhance our position in medical biomaterials.”
Christophe Douat, CEO of MedinCell, added, “The creation of CM Biomaterials validates our balanced network company model that aims to gather leaders in many fields to create best-in-class medicines for Global Health. Based on a complementary partnership, CM Biomaterials will best serve BEPO partners and secure the quality of the polymers used for all BEPO applications.”
Based on a combination of co-polymers, solvent and active pharmaceutical ingredient (API), the BEPO technology can provide a controlled release of drug for days, weeks or months from a fully biodegradable depot that forms after subcutaneous injection or local delivery of the formulated API. As a game-changing technology, BEPO combines many advantages compared to alternative drug delivery technologies, including improved patient compliance, efficacy and tolerability, as well as, versatility, development speed and lower manufacturing costs.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%